In pur­suit of a block­buster, Am­gen and As­traZeneca score pri­or­i­ty re­view for asth­ma drug teze­pelum­ab

Am­gen and As­traZeneca are one big step clos­er to re­al­iz­ing their block­buster dreams for teze­pelum­ab af­ter the FDA grant­ed a pri­or­i­ty re­view for the asth­ma drug.

De­spite the chal­lenge of bat­tling Re­gen­eron and Sanofi’s Dupix­ent, teze­pelum­ab has been pegged for peak sales of $2.5 bil­lion. With As­traZeneca lead­ing de­vel­op­ment, Am­gen spear­head­ing man­u­fac­tur­ing and both shar­ing com­mer­cial­iza­tion re­spon­si­bil­i­ties, the two phar­ma gi­ants have been vo­cal about their op­ti­mism.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.